X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (838) 838
Newsletter (123) 123
Publication (39) 39
Book Review (14) 14
Magazine Article (8) 8
Book Chapter (2) 2
Dissertation (2) 2
Trade Publication Article (2) 2
Conference Proceeding (1) 1
Data Set (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
rabeprazole (850) 850
humans (539) 539
pharmacology & pharmacy (435) 435
omeprazole (375) 375
male (372) 372
proton pump inhibitors (359) 359
female (298) 298
lansoprazole (289) 289
adult (267) 267
index medicus (257) 257
2-pyridinylmethylsulfinylbenzimidazoles (252) 252
gastroenterology & hepatology (231) 231
middle aged (220) 220
omeprazole - analogs & derivatives (211) 211
proton pump inhibitor (138) 138
esomeprazole (128) 128
helicobacter pylori (126) 126
aged (122) 122
anti-ulcer agents - therapeutic use (122) 122
helicobacter infections - drug therapy (119) 119
gastroesophageal reflux - drug therapy (117) 117
pantoprazole (116) 116
pharmacokinetics (115) 115
treatment outcome (113) 113
benzimidazoles - pharmacology (109) 109
gastroesophageal reflux (103) 103
benzimidazoles - therapeutic use (100) 100
cytochrome p-450 cyp2c19 (100) 100
anti-ulcer agents - pharmacology (98) 98
omeprazole - pharmacology (95) 95
hydrogen-ion concentration (92) 92
drug interactions (91) 91
cross-over studies (88) 88
gastroesophageal-reflux disease (87) 87
anti-ulcer agents - administration & dosage (83) 83
drug therapy, combination (81) 81
pharmacology (81) 81
aryl hydrocarbon hydroxylases - genetics (75) 75
proton pump inhibitors - pharmacology (75) 75
cyp2c19 (74) 74
omeprazole - therapeutic use (74) 74
amoxicillin (73) 73
genotype (73) 73
animals (71) 71
proton pump inhibitors - therapeutic use (71) 71
pharmacology/toxicology (70) 70
cytochrome p-450 (68) 68
intragastric ph (68) 68
young adult (68) 68
proton pump inhibitors - administration & dosage (67) 67
2-pyridinylmethylsulfinylbenzimidazoles - administration & dosage (66) 66
medicine & public health (66) 66
care and treatment (65) 65
benzimidazoles - administration & dosage (64) 64
clarithromycin (64) 64
helicobacter pylori - drug effects (63) 63
double-blind method (61) 61
adolescent (60) 60
drugs (60) 60
2-pyridinylmethylsulfinylbenzimidazoles - pharmacology (58) 58
enzyme inhibitors - pharmacology (58) 58
gastroesophageal reflux disease (58) 58
metabolism (58) 58
research (58) 58
infection (57) 57
omeprazole - administration & dosage (56) 56
double-blind (55) 55
efficacy (53) 53
dose-response relationship, drug (52) 52
universities and colleges (52) 52
e3810 (51) 51
gastric acid - secretion (50) 50
gastric acidity determination (50) 50
medical research (50) 50
internal medicine (49) 49
triple therapy (49) 49
area under curve (48) 48
helicobacter-pylori infection (48) 48
medicine, experimental (48) 48
analysis (47) 47
therapy (47) 47
anti-bacterial agents - therapeutic use (46) 46
anti-ulcer agents - pharmacokinetics (45) 45
gastric acid - metabolism (45) 45
dosage and administration (44) 44
drug therapy (44) 44
2-pyridinylmethylsulfinylbenzimidazoles - therapeutic use (43) 43
benzimidazoles - pharmacokinetics (43) 43
mixed function oxygenases - genetics (43) 43
proton-pump inhibitors (43) 43
drug administration schedule (42) 42
2-pyridinylmethylsulfinylbenzimidazoles - pharmacokinetics (41) 41
administration, oral (41) 41
amoxicillin - administration & dosage (41) 41
polymorphism, genetic (40) 40
management (39) 39
omeprazole - pharmacokinetics (39) 39
rabeprazole sodium (39) 39
enzyme inhibitors - therapeutic use (38) 38
esophagitis (38) 38
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (933) 933
Japanese (21) 21
French (5) 5
Chinese (2) 2
German (2) 2
Hungarian (2) 2
Russian (2) 2
Spanish (2) 2
Italian (1) 1
Polish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Clinical Pharmacology & Therapeutics, ISSN 0009-9236, 01/2011, Volume 89, Issue 1, pp. 65 - 74
Four randomized, placebo‐controlled, crossover studies were conducted among 282 healthy subjects to investigate whether an interaction exists between... 
VARIABILITY | LANSOPRAZOLE | RABEPRAZOLE | THERAPY | CARDIOVASCULAR EVENTS | STENT PLACEMENT | PHARMACOLOGY & PHARMACY | OUTCOMES | ANTIPLATELET ACTION | PROTON-PUMP INHIBITORS | DRUG-INTERACTION | Proton Pump Inhibitors - pharmacology | Ticlopidine - pharmacology | Humans | Middle Aged | Half-Life | Male | 2-Pyridinylmethylsulfinylbenzimidazoles - pharmacology | Enzyme Inhibitors - administration & dosage | Platelet Aggregation Inhibitors - blood | Young Adult | Drug Interactions | Proton Pump Inhibitors - administration & dosage | Platelet Aggregation Inhibitors - pharmacology | Adult | Female | Omeprazole - pharmacology | Platelet Aggregation - drug effects | Platelet Aggregation Inhibitors - pharmacokinetics | Ticlopidine - pharmacokinetics | Enzyme Inhibitors - adverse effects | Proton Pump Inhibitors - adverse effects | Aryl Hydrocarbon Hydroxylases - antagonists & inhibitors | Double-Blind Method | Drug Administration Schedule | 2-Pyridinylmethylsulfinylbenzimidazoles - adverse effects | Omeprazole - administration & dosage | Enzyme Inhibitors - pharmacology | Omeprazole - adverse effects | Ticlopidine - analogs & derivatives | Cross-Over Studies | Prodrugs - adverse effects | Prodrugs - pharmacokinetics | Cytochrome P-450 CYP2C19 | Platelet Activation - drug effects | 2-Pyridinylmethylsulfinylbenzimidazoles - administration & dosage | Prodrugs - pharmacology | Ticlopidine - blood | Omeprazole | Pantoprazole | Drug interactions | Analysis | Dosage and administration | Research | Patients | Health aspects
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 7/2016, Volume 78, Issue 1, pp. 41 - 49
The Hedgehog pathway inhibitor vismodegib exhibits pH-dependent solubility, and in vitro studies have shown that vismodegib is a substrate of P-glycoprotein... 
Medicine & Public Health | CYP inhibitors | Clinical pharmacology | Oncology | Cancer Research | Pharmacology/Toxicology | Clinical drug–drug interaction | Pharmacokinetic | Proton-pump inhibitor | P-glycoprotein inhibitor | SINGLE | HUMAN PLASMA | ORAL ABSORPTION | MASS-SPECTROMETRY | GDC-0449 | ONCOLOGY | Clinical drug-drug interaction | PHARMACOLOGY & PHARMACY | HEALTHY-VOLUNTEERS | HEDGEHOG SIGNALING PATHWAY | SOLID-PHASE EXTRACTION | Fluconazole - pharmacology | Proton Pump Inhibitors - pharmacology | Cytochrome P-450 CYP3A Inhibitors - administration & dosage | Pyridines - administration & dosage | Cytochrome P-450 CYP3A Inhibitors - pharmacology | Area Under Curve | Humans | ATP-Binding Cassette, Sub-Family B, Member 1 - metabolism | Fluconazole - administration & dosage | Solubility | Pyridines - pharmacokinetics | Anilides - pharmacokinetics | ATP-Binding Cassette, Sub-Family B, Member 1 - antagonists & inhibitors | Itraconazole - pharmacology | Cytochrome P-450 CYP2C9 Inhibitors - administration & dosage | Cytochrome P-450 CYP2C9 Inhibitors - pharmacology | Drug Interactions | Anilides - administration & dosage | Proton Pump Inhibitors - administration & dosage | Rabeprazole - pharmacology | Female | Itraconazole - administration & dosage | Hydrogen-Ion Concentration | Rabeprazole - administration & dosage | Drug interactions | Cytochrome P-450 | Original
Journal Article
European Journal of Drug Metabolism and Pharmacokinetics, ISSN 0378-7966, 2009, Volume 34, Issue 1, pp. 19 - 26
Journal Article
Alimentary Pharmacology & Therapeutics, ISSN 0269-2813, 11/2013, Volume 38, Issue 9, pp. 1129 - 1137
Journal Article
PLoS ONE, ISSN 1932-6203, 2011, Volume 6, Issue 7, p. e22163
Journal Article
Journal Article
Drug Design, Development and Therapy, ISSN 1177-8881, 02/2017, Volume 11, pp. 451 - 461
Inhibitors targeting the amplification of the fibroblast growth factor receptor 1 (FGFR1) have found success in the treatment of FGFR1-positive squamous cell... 
Theoretical study | Gatekeeper mutation | V561M | FGFR1 | Resistance mechanisms | gatekeeper mutation | MOLECULAR-DYNAMICS | COMPLEX | CHEMISTRY, MEDICINAL | theoretical study | SENSITIVITY | resistance mechanisms | AMBER | PACKAGE | PHARMACOLOGY & PHARMACY | INHIBITOR | BINDING | Humans | Piperazines - chemistry | Antineoplastic Agents - chemistry | Receptor, Fibroblast Growth Factor, Type 1 - genetics | Piperazines - pharmacology | Receptor, Fibroblast Growth Factor, Type 1 - antagonists & inhibitors | Molecular Dynamics Simulation | Drug Resistance, Neoplasm - genetics | Protein Kinase Inhibitors - chemistry | Pyrazoles - chemistry | Rabeprazole - chemistry | Rabeprazole - pharmacology | Antineoplastic Agents - pharmacology | Benzamides - pharmacology | Molecular Docking Simulation | Protein Kinase Inhibitors - pharmacology | Receptor, Fibroblast Growth Factor, Type 1 - chemistry | Benzamides - chemistry | Drug Resistance, Neoplasm - drug effects | Pyrazoles - pharmacology | Fibroblast growth factor | Computer simulation | Molecular dynamics | Drug resistance | Free energy | Molecular docking | Inhibitors | Lungs | Computer applications | Affinity | Mutation | Surface area | Fibroblast growth factor receptor 1 | Binding sites | Theory | Kinases | Proteins | Energy | Fibroblasts | Growth factors | Therapeutic applications | Breast cancer | Simulation | Ligands | Methods | Tumors
Journal Article
Journal Article
Clinical Therapeutics, ISSN 0149-2918, 2010, Volume 32, Issue 12, pp. 2003 - 2011
Journal Article